- Home
- CRBP vs CHRS Comparison
CRBP vs CHRS Comparison
Compare CRBP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- CHRS
- Stock Information
- Founded
- CRBP 2009
- CHRS 2010
- Country
- CRBP United States
- CHRS United States
- Employees
- CRBP N/A
- CHRS N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRBP Health Care
- CHRS Health Care
- Exchange
- CRBP Nasdaq
- CHRS Nasdaq
- Market Cap
- CRBP 96.5M
- CHRS 84.2M
- IPO Year
- CRBP N/A
- CHRS 2014
- Fundamental
- Price
- CRBP $8.22
- CHRS $0.90
- Analyst Decision
- CRBP Strong Buy
- CHRS Buy
- Analyst Count
- CRBP 10
- CHRS 3
- Target Price
- CRBP $53.56
- CHRS $4.68
- AVG Volume (30 Days)
- CRBP 214.0K
- CHRS 1.2M
- Earning Date
- CRBP 08-05-2025
- CHRS 08-07-2025
- Dividend Yield
- CRBP N/A
- CHRS N/A
- EPS Growth
- CRBP N/A
- CHRS N/A
- EPS
- CRBP N/A
- CHRS N/A
- Revenue
- CRBP N/A
- CHRS $272,251,000.00
- Revenue This Year
- CRBP N/A
- CHRS N/A
- Revenue Next Year
- CRBP $150.03
- CHRS $106.56
- P/E Ratio
- CRBP N/A
- CHRS N/A
- Revenue Growth
- CRBP N/A
- CHRS 19.87
- 52 Week Low
- CRBP $4.64
- CHRS $0.66
- 52 Week High
- CRBP $61.90
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- CRBP 54.23
- CHRS 59.04
- Support Level
- CRBP $7.26
- CHRS $0.73
- Resistance Level
- CRBP $7.90
- CHRS $0.82
- Average True Range (ATR)
- CRBP 0.53
- CHRS 0.04
- MACD
- CRBP -0.01
- CHRS 0.02
- Stochastic Oscillator
- CRBP 78.59
- CHRS 88.02
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.